At the beginning of the intervention, eligible patients with T2D and ASCVD, CKD, and/or HF were identified by the Patient Report as potentially benefiting from SGLT2 inhibitor or GLP-1 RA initiation. This evidence concerns the gene SLC5A2 and atherosclerosis.